Polarographic Electrode Study of Tumor Oxygenation in Clinically Localized Prostate Cancer
Overview
Authors
Affiliations
Purpose: To describe the oxygenation of clinically localized prostate cancer.
Methods And Materials: Intraprostatic oxygen tension was measured using the Eppendorf electrode in 55 unanesthetized men with localized prostate cancer before radiotherapy. Measurements were made along two tracks through regions of suspected tumor in the prostate, and core needle biopsies were then obtained from the same regions.
Results: The median pO(2) ranged from 0.2 to 57.3 mm Hg, and the grand median pO(2) was 4.5 mm Hg. The percentage of oxygen readings <5 mm Hg (HP(5)) ranged from 0% to 100% (median 60%). The track 1 oxygen readings were greater than those from track 2. Statistically significant heterogeneity was found in the individual oxygen readings: the between- and within-tumor components accounted for 32% and 68% of the total variability, respectively. However, the between-tumor variability in HP(5) significantly exceeded the within-tumor variability (61% vs. 39%). No association was found between oxygen values and clinical factors, including age, T stage, Gleason score, prostate-specific antigen level, hemoglobin concentration, or prior hormonal treatment. No difference was noted in the oxygenation between regions of tumor and normal prostate tissue, as determined from the core biopsies.
Conclusion: Localized prostate cancer is characterized by marked hypoxia and significant heterogeneity in oxygenation, similar to other human tumors. The normal prostate may contain regions of low oxygen concentration. HP(5), as determined in this study, should adequately discriminate among patients with prostate cancer and allow the independent prognostic significance of oxygenation to be evaluated once the study matures.
Oxygen Assessment in Tumors In Vivo Using Phosphorescence Lifetime Imaging Microscopy.
Komarova A, Shcheslavskiy V, Plekhanov A, Sirotkina M, Bochkarev L, Shirmanova M Methods Mol Biol. 2024; 2755:91-105.
PMID: 38319571 DOI: 10.1007/978-1-0716-3633-6_6.
Feng D, Wang J, Li D, Wu R, Wei W, Zhang C Discov Oncol. 2023; 14(1):155.
PMID: 37624511 PMC: 10457268. DOI: 10.1007/s12672-023-00777-1.
The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.
Ma C, Zhou Y, Fanelli G, Stopsack K, Fiorentino M, Zadra G Mol Cancer Res. 2022; 21(3):253-260.
PMID: 36511902 PMC: 9991973. DOI: 10.1158/1541-7786.MCR-22-0627.
Abu El Maaty M, Terzic J, Keime C, Rovito D, Lutzing R, Yanushko D Sci Adv. 2022; 8(29):eabo2295.
PMID: 35867798 PMC: 9307253. DOI: 10.1126/sciadv.abo2295.
Brown M, Rebillard A, Hart N, OConnor D, Prue G, OSullivan J Sports Med Open. 2022; 8(1):48.
PMID: 35394236 PMC: 8993953. DOI: 10.1186/s40798-022-00436-9.